July 2020

Important Information

2

The following presentation, including any printed or electroniccopy of these slides, the talks given by the presenters, theinformation communicated during any delivery of thepresentation and any question and answer session and anydocument or material distributed at or in connection with thepresentation (together, the "Presentation"), has been prepared byPureTech Health plc (the "Company"). The information in thePresentation is not intended to form the basis of any contract.By attending (whether in person or by telephone) or reading thePresentation, you agree to the conditions set out below.

THIS DOCUMENT AND THE PRESENTATION IS NOT APROSPECTUS. The Presentation does not constitute or form partof any offer or invitation to sell or issue, or any solicitation of anyoffer to purchase or subscribe for, any shares or other securitiesof the Company, nor shall there be any sale of these securities inany state or jurisdiction in which such offer, solicitation or salewould be unlawful prior to registration or qualification under thesecurities laws of any such state or jurisdiction. Any suchoffering of securities will only be made by means of a registrationstatement (including a prospectus) filed with the Securities andExchange Commission (the "SEC"), after such registrationstatement becomes effective. No such registration statementhas been filed as of the date of this presentation.

This document and the Presentation contain statements that areor may be forward-looking statements. These statements arebased on our management’s current beliefs, expectations andassumptions about future events, conditions and results, and oninformation currently available to us. This document and thePresentation also contain estimates and other statistical datamade by independent parties and by us relating to market sizeand growth and other data about our industry. This data involvesa number of assumptions and limitations, and you are cautionednot to give undue weight to such estimates. In addition,

projections, assumptions and estimates of our futureperformance and the future performance of the markets in whichwe operate are necessarily subject to a high degree ofuncertainty and risk.

All statements other than statements of historical facts includedin this document may be forward-looking statements, includingstatements that relate to the Company's future prospects,developments and strategies. Words such as “expect,”“anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “think,”“may,” “could,” “will,” “would,” “should,” “continue,” “potential,”“likely,” “opportunity” and similar expressions or variations ofsuch words are intended to identify forward-looking statements,but are not the exclusive means of identifying forward-lookingstatements. Additionally, statements concerning future matterssuch as our expectations of business and market conditions,development and commercialization of new products,enhancements of existing products or technologies, and otherstatements regarding matters that are not historical are forward-looking statements. Such statements are based on currentlyavailable operating, financial and competitive information and aresubject to various risks, uncertainties and assumptions thatcould cause actual results to differ materially from thoseanticipated or implied in our forward-looking statements due to anumber of factors including, but not limited to:

The Company’s business is subject to a number of risks anduncertainties. These risks are described in the Company’s mostrecent Annual Report and Accounts which can found on theCompany’s web site at http://puretechhealth.com/investors-reports-presentations.php.

Given these risks, uncertainties and other factors, many of whichare beyond the Company’s control, you should not place unduereliance on these forward-looking statements.

Each forward-looking statement speaks only as at the date ofthis document. Except as required by law, we assume noobligation to update these forward-looking statements publicly,or to revise any forward-looking statements to reflect events ordevelopments occurring after the date of this document, even ifnew information becomes available in the future.

The Presentation is confidential and should not be distributed,published or reproduced (in whole or in part) or disclosed by itsrecipients to any other person for any purpose, other than withthe consent of the Company.

By attending any delivery of, or electronically accessing, thePresentation, you agree to be bound by the above limitations andconditions and, in particular, you represent, warrant andundertake to the Company that: (i) you will not retain in anymanner the Presentation or forward the Presentation to any otherperson, or reproduce or publish this document, in whole or in part,for any purpose and (ii) you have read and agree to comply withthe contents of this notice.

This presentation is being made in reliance upon Section 105(c)of the Jumpstart Our Business Startup Act of 2012, as amended,and is intended solely for investors that are either qualifiedinstitutional buyers or institutions that are accredited investors(as such terms are defined under SEC rules).

References in the following presentation to our “ControlledFounded Entities” refer to Alivio Therapeutics, Inc., Follica,Incorporated, Entrega, Inc., Vedanta Biosciences, Inc., and SondeHealth, Inc. References to our “Non-Controlled Founded Entities”refer to Akili Interactive Labs, Inc., Karuna Therapeutics, Inc., VorBiopharma, Inc., Gelesis, Inc., and, for all periods prior toDecember 18, 2019, resTORbio, Inc.

PureTech: An advanced biotherapeutics company with a productive R&D engine

3

1 PureTech Level Pro-forma Cash Reserves is an alternative performance measure (APM) which includes the PureTech Level Cash Reserves of $120.6 million and the $200.9 million in proceeds from the January 22, 2020 sale of 2.1 million Karuna common shares. PureTech Pro-forma Cash Reserves is therefore considered to be more representative of the Corporate’s cash available for the year 2020 and beyond to advance product candidates within the full breadth of its operations; 244.5 million in proceeds from the May 22, 2020 sale of 555.5 thousand Karuna common shares. 3 PureTech Level Cash Reserves represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, and PureTech Securities Corporation of $112.0 million for the year ended 2019 and the internal pipeline of $8.6 million for the year ended 2019, all of which are wholly-owned entities of PureTech, excluding cash balances and short-term investments of Controlled Founded Entities. The balance excludes the $200.9 million in proceeds from the January 22, 2020 sale of 2.1 million Karuna common and the 44.5 million in proceeds from the May 22, 2020 sale of 555.5 thousand Karuna common shares.; 4Across PureTech and its Controlled and Non-Controlled Founded Entities; 5Funding figure includes private equity financings, public offering, and grant awards. Funding figure excludes upfront payments and future milestone considerations received in conjunction with partnerships and collaborations such as those with Roche, Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd., and Eli Lilly. Number represents figure from January 1 – June 30, 2020. $758.8m (94.5%) came from third parties.

24 products and product candidates

and

13 are clinical stageof which

2 are FDA-cleared

Cash runway into 2024 via$321.5M Pro-forma Cash

Reserves at PRTC Parent Level1

$803.3M raised by Founded Entities since 20195

94% from third-parties

LSE Main Market (PRTC) FTSE 250

Relationships with multiple major pharma companies

or their investment arms4

Additional $45M Cash from Founded Equity Saleon May 25, 20202

Prior to receipt of proceeds from monetization of Founded Entities $120.6M Cash Reserves at PRTC

Parent Level as of December 31, 20193

Proven Team of Senior Executives

4

Oversaw R&D of products supporting 20 regulatory approvals and were in C-suite of companies acquired for more than $13 billion in the aggregate

Drove formation of team, scientific network & pipeline; Recognized as a top leader in biotech by EY, Scientific American, BioWorld & others; Board Member

Daphne Zohar Founder & Chief Executive Officer

Former COO Auspex (acq by Teva $3.5B), Nektar ($3B+ MC), GC SIRNA (acq by Merck $1.1B)

Bharatt Chowrira, PhD, JD President & Chief of Business and Strategy

Co-inventor of several PureTech external/internal programs; Formerly McKinsey, UCSD

Eric Elenko, PhD Co-founder & Chief Innovation Officer

Former CSO Millennium (acq. by Takeda $8.8B), Moderna, TA Head Oncology BMS

Joseph Bolen, PhD Chief Scientific Officer

Former Portfolio Manager at Life Sciences Partners, a leading European biotech investor group

Joep Muijrers, PhDChief of Portfolio Strategy

Former Partner Locke Lorde; Board Member

Stephen Muniz, Esq Co-founder & Chief Operating Officer

Former CEO & Board Member at Sanofi, Former President & Board Member at GSK

Christopher Viehbacher Board Chairman

MIT, Award winning materials science pioneer, Former member of the United States FDA’s SCIENCE Board

Robert Langer, ScDBoard and R&D Committee

Director of CATCH at MGH/MIT, Professor at HMS, Former Chief of Medicine at MGH, Board Director Alnylam, Former Pfizer Board

Dennis Ausiello, MDR&D Committee and Board Advisor

MIT, HHMI, Nobel Prize in Medicine, Scientific Advisory Board at Mitobridge & MPM Capital

Robert Horvitz, PhD R&D Committee Chair and Board Advisor

Former CEO Pearson, Former MacArthur Foundation Chair, Former Twitter Board

Dame Marjorie ScardinoBoard

Ben Shapiro, MDR&D Committee and Board Advisor

Former EVP of Research at Merck

Former President of Pfizer Global R&D

John LaMattina, PhDBoard and R&D Committee

Experienced Board of Directors and R&D Committee

5

Our board contributed to regulatory approvals of approximately 30 drugs, led multiple multi-billion dollar strategic transactions, and co-founded multiple companies

Harvard, Co-Founder of Millennium (acq. by Takeda $8.8B) & Abgenix (acq. by Amgen $2.2B)

Raju Kucherlapati, PhDBoard and R&D Committee

A unique collaborative research & development model for advancing new medicines

6The Brain-Immune-Gut (BIG) Axis: ~70% of immune cells and 500M neurons converge in the GI tract

Disease focused drug discovery based on proprietary insights and collaboration with the world’s leading experts on Brain, Immune, Gut

Successful model for bringing innovative medicines to patients

Collaborate with world’s leading domain experts on disease-specific discovery theme through the lens of

BIG Axis biology

Develop internally, partner, or advance through subsidiary

Value

Rigorous and disciplined approach to develop, de-

risk and validate the candidates in a cost-

effective way

VALIDATIONUnbiased Scientific

INNOVATION REALIZATIONBoundless

7

Our model enables the allocation of resources and cash to the most promising programs

34.4% Equity FDA Cleared,CE Mark 11.8% Equity Preclinical

PureTech’s Components of Value

78.6% Equity Preclinical

78.3% Equityplus Royalties Phase 3 Ready

45.9% Equity Phase 153.3% Equity Phase 2

22.0% Equityplus Royalties

FDA Cleared,CE Mark

(KRTX)18.1% Equityplus Royalties

Phase 3 Ready2

1This figure represents the stage of development for each Founded Entity’s most advanced product candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representation to the entities’ board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of December 31, 2019 (with the exception of Gelesis ownership which is as of April 1, 2020), including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Ownership of Vor (calculated as of June 30, 2020) and Sonde is based on the assumption that all future tranches of their most recent financing rounds are funded. Karuna ownership is calculated on an outstanding voting share basis as of May 26, 2020.; 2Following the completion of a successful End-of-Phase 2 meeting with the US FDA, Karuna remains on track to initiate the Phase 3 program by the end of 2020.; 3PureTech Level Pro-forma Cash Reserves is an alternative performance measure (APM) which includes the PureTech Level Cash Reserves of $120.6 million and the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares. PureTech Pro-forma Cash Reserves is therefore considered to be more representative of the Corporate’s cash available for the year 2020 and beyond to advance product candidates within the full breadth of its operations.; 4$44.5 million in proceeds from the May 22, 2020 sale of 555.5 thousand Karuna common shares.; 5PureTech Level Cash Reserves represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, and PureTech Securities Corporation of $112.0 million for the year ended 2019 and the internal pipeline of $8.6 million for the year ended 2019, all of which are wholly-owned entities of PureTech, excluding cash balances and short-term investments of Controlled Founded Entities. The balance excludes the $200.9 million in proceeds from the January 22, 2020 sale of 2.1 million Karuna common and the 44.5 million in proceeds from the May 22, 2020 sale of 555.5 thousand Karuna common shares.

72.9% Equity Preclinical

8

Founded Entities1

Cash at PureTech Parent Level

Wholly Owned Pipeline

Cash runway into 2024 via$321.5M Pro-forma Cash Reserves at PRTC

Parent Level3

Additional $45M Cash from Founded Equity Saleon May 25, 20204

Prior to receipt of proceeds from monetization of Founded Entities $120.6M Cash Reserves at PRTC

Parent Level as of December 31, 20195

Karuna (PRTC Ownership: 18.1% plus royalties*)Selectively activating muscarinic acetylcholine receptors in the brain

9*As of May 26, 2020, PureTech’s percentage ownership of Karuna was approximately 18.1 percent on an outstanding share basis. PureTech Health has a right to royalty payments as a percentage of net sales from Karuna. 1Return on Investment and value creation calculations were assessed based on PureTech’s percentage ownership of Karuna outstanding shares as of market close June 30, 2020. 2$200.9 million in proceeds from the January 22, 2020 sale of 2.1 million Karuna common shares and $44.5 million in proceeds from the May 25, 2020 sale of 555.5 thousand Karuna common shares.

Nasdaq IPO, Phase 2 data

KarXT for schizophrenia met the primary endpoint with a clinically meaningful 11.6 point improvement on the PANSS total score

Built top team of CNS experts led by former Lilly executive Steven Paul, MD

XanomelineCNS active agonistTrospium chloride Peripheral antagonist blocks side effects of agonist

Muscarinic agonist

Muscarinic antagonist

Current antipsychotics all rely on the same fundamental mechanism of action and are plagued with tolerability and compliance issues

Positive outcome of End-of-Phase 2 meeting with FDA; initiation of Phase 3 program by end of 2020

~2.7M living with schizophrenia in the US

Completed tolerability POC

Planned Phase 2 POC study

Invented and filed patents to cover the approach

Exclusively in-licensed xanomeline from Eli Lilly

$18.5M total PRTC spend

$774M value created1

$245M of which is cash generated from equity sales2

42XROI1

Potential to target additional indications, including dementia-related psychosis and pain

Advised by world’s leading schizophrenia & dementia-related psychosis experts:

ValidationInnovation Realization

Gelesis (PRTC Ownership: 22.0% plus royalties*)FDA-cleared for the broadest patient population of any weight management product

10

*As of 1 April 2020, PureTech’s percentage ownership of Gelesis was approximately 22.0 percent on a diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans and assumes all committed tranches are funded in the Series 3 Growth financing round. PureTech has a right to royalty payments as a percentage of net sales from Gelesis.; 1Important Safety Information: Plenity is contraindicated in patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide. Plenity may alter the absorption of medications. Read Sections 6 and 8.3 of the Instructions for Use carefully. Avoid use in patients with the following conditions: esophageal anatomic anomalies, including webs, diverticuli, and rings; suspected strictures (such as patients with Crohn’s disease); or complications from prior gastrointestinal (GI) surgery that could affect GI transit and motility. Use with caution in patients with active GI conditions such as gastro-esophageal reflux disease (GERD), ulcers or heartburn. The overall incidence of adverse events (AEs) in the Plenity group was no different than the placebo group. The most common side effects were diarrhea,distended abdomen, infrequent bowel movements, and flatulence. For the safe and proper use of Plenity, refer to U.S. Instructions for Use or the EU Instructions for Use.

Prescribed therapeutics for obesity are systemically and centrally acting with potential for serious safety concerns Phase 3 Pivotal Trial Met Primary Endpoint

with 59% of adults with overweight or obesity had a clinically meaningful response to Plenity, losing on average 10% of their weight (22 pounds) over 6 months

Partnership with Ro to support US commercialization of Plenity

Partnership with China Medical System Holdingsfor the commercialization of Plenity in China; includes $35 million up front, with future milestone payments of up to $388 million plus royalties

Developing oral therapeutics to target chronic diseases such as NAFLD/NASH, Mucositis/IBD, Chronic Constipation (CIC)

~150M individuals in the US with overweight and obesity within Plenity’s label

Broad US launch of Plenity anticipated in 2021

Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases.

Planned and completed POC studies

Planned Phase 2 POC study

Identified and in-licensed the core IP from collaborator Alessandro Sannino, PhD

Co-invented additional IP around a novel class of biocompatible, superabsorbent hydrogels

Advised by world’s leading experts:

FDA-cleared Plenity®1 for the broadest patient population of any weight management product (BMI 25-40 kg/m2)

FDA Clearance & European CE Mark

ValidationInnovation Realization

Akili (PRTC Ownership: 34.4%*)First game-based digital therapeutic cleared by the FDA for ADHD

11*As of 31 December 2019, PureTech’s percentage ownership of Akili was approximately 34.4 percent on a diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans.

FDA Clearance & European CE Mark

FDA cleared for pediatric patients age 8 to 12 years old with primarily inattentive or combined-type ADHD who have a demonstrated attention issue

EndeavorRxTM (AKL-T01), in a pivotal study for pediatric ADHD, showed a statistically significant improvement on the primary endpoint, a composite score from the Test of Variables of Attention (T.O.V.A.®)

Commercial and development partnership with Shionogi in Japan and Taiwan; includes $20 million in up front payments and the potential to receive milestone payments for an additional $105 million, in addition to substantial royalties on product sales

Potential to target cognitive impairments in other indications: ASD, MDD, MS, MCI andTBI

Helped to build top development and commercial team and raise funds The treatment of many neuropsychiatric

disorders is only partially served, or not served at all, by currently available medications or by in-person behavioral therapy

~6.4M pediatric ADHD patients in the US

Planned and completed initial pilot and POC studies

Engaged with leading experts who had been studying the effects of video games on cognition and the underlying neural processes accessible by sensory stimulation

Identified and in-licensed from University of California, San Francisco (UCSF) the intellectual property invented by Adam Gazzaley, MD, PhD

Oversaw the initial product development and design

ValidationInnovation Realization

100%

90.0%

60%

60%

63%

31%

18%

11%

0% 20% 40% 60% 80% 100%

Phase 1Success

Phase 1 &2 Success

Phase 2 &3 Success

Phase 1, 2& 3

Success

PureTech Industry Average

PureTech has a track record of creating significant multiples of value…

1 IRR over a 10 year period (since January 2010) according to historical PureTech investment and realized and unrealized gains; including the following Founded Entities (Gelesis, Karuna, Vedanta, Akili, resTORbio, Entrega, Follica, Sonde, Alivio, Vor, Tal, Sync, Commense and PureTech Corporate expenses as well as adjusted for management ownership of PureTech; 2PureTech clinical trial success defined as a positive readout and not all product candidates conducted a Phase 1 clinical trial; Akili and Gelesis are regulated as devices; 3 Includes clinical trials from 2009 onward; 4 Industry average data measures the probability of clinical trial success of therapeutics. BIO, Biomedtracker, Amplion (2015) Clinical Development Success Rates 2006 – 2015.

51% IRRFounded Entities

(2009 to present)1

PureTech has demonstrated high probabilities of clinical success; particularly notable in the stages where

industry failures are typically high

42, 3

12

24 products and product candidates

of which

2were taken from inception to FDA Regulatory Clearance

42XROI from Karuna (KRTX)

(2009 to present)

…and is set to replicate this success through the Wholly-Owned Pipeline

13

Wholly Owned Pipeline represents a key source of future growth, with value expected to be retained within PureTech, supported by

our strong cash position

Founded Entities1 Wholly Owned Pipeline

34.4% Equity FDA Cleared,CE Mark 11.8% Equity Preclinical

78.6% Equity Preclinical

78.3% Equityplus Royalties Phase 3 Ready

45.9% Equity Phase 153.3% Equity Phase 2

22.0% Equityplus Royalties

FDA Cleared,CE Mark

(KRTX)18.1% Equity

plus RoyaltiesPhase 3 Ready2

72.9% Equity Preclinical

Our Founded Entities are a validation of PureTech’s model, and a significant source of value and upside

20202009

Discovery Preclinical Phase 1 Phase 2OUR PROGRAMS

Initiation of POC study in 2020LYT-100Deupirfenidone Lymphatic flow disorders, incl. lymphedema

LYT-100Deupirfenidone

COVID-19 post-recovery respiratory complications

LYT-210Anti-Delta-1 MAb GI autoimmunity

LYT-210Anti-Delta-1 MAb Solid tumors

LYT-200Anti-Galectin-9 MAb Solid tumors IND and initiation of Phase 1 study in 2020

MENINGEAL LYMPHATICSPlatform

MILK EXOSOMEPlatform

LYMPHATIC TARGETINGChemistry Platform

Orphan & other neurological indications

Initiation of POC study in Q3 2020

LYT-100Deupirfenidone Other fibrotic & inflammatory disorders

1 This figure represents the stage of development for each Founded Entity’s most advanced product candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representation to the entities’ board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of December 31, 2019 (with the exception of Gelesis ownership which is as of April 1, 2020), including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Ownership of Vor (calculated as of June 30, 2020) and Sonde is based on the assumption that all future tranches of their most recent financing rounds are funded. Karuna ownership is calculated on an outstanding voting share basis as of May 26, 2020.; 2Following the completion of a successful End-of-Phase 2 meeting with the US FDA, Karuna remains on track to initiate the Phase 3 program by the end of 2020.

Wholly OwnedHarnessing functions of the lymphatic system to develop PureTech’s internal programs

The mesenteric lymph nodes are the major

interface between the gut and immune system

Maintaining balance of fluidAddressing disorders involving lymphatic flow and lymphatic vessel restoration

Immune cell trafficking & programmingTargeting galectin-9 and immunomodulatory γδ1 T cells and related mechanisms with fully human mAbs

Absorbing dietary fatCommandeering the lymphatic system’s function of absorbing dietary fat to traffic therapeutics through the lymphatics

1

3

2

14

The BIG Axis: Lymphatic system connects all tissues to regional lymph nodes

Significant opportunity for an anti-fibrotic and anti-inflammatory approachDiscovery process

Wholly Owned LYT-100 development process

Stanley RocksonStanford Medicine

Babak MehraraMemorial Sloan Kettering

World’s leading lymphedema experts with proprietary insights & unpublished data:

A healthy lymphatic system drains interstitial fluid

Damaged lymphatics fail to drain

PureTech senior team member knowledge of LYT-100 clinical data & relationships (Auspex/Teva)

Fibrosis driven by TGF-β

Inflammation and pro-inflammatory cytokines, e.g.,

IL-6 and TNF-α

Anti-inflammatories do not address fibrosis-related

functional impairment

Anti-fibrotics limited by significant

tolerability issues

Need to target both mechanisms

Lymphatic Disorders

Lung Diseases

Other Inflammatory / Fibrotic Disorders

Inflammation Fibrosis

LYT-100 is a potent anti-inflammatory and anti-fibrotic molecule entering Phase 2 clinical development in 2020

15

Wholly Owned LYT-100 (deupirfenidone): Efficacy & tolerability advantages w/ pirfenidone’s de-risked clinical profile

19 large pills per day

Deuteration modifies metabolism

Short half-life and metabolic profile create limitations including: Differentiated PK profile provides potential advantages including:limited exposure enhanced exposure

frequent TID dosing & significant pill burden issues1 less frequent dosing & reduced pill burden

tolerability issues improved tolerability

dose-limited efficacy increased efficacy

No Composition of Matter Patent – currently under Orphan Drug Exclusivity

505(b)(2) pathway

Issued Composition of Matter Patent - exclusivity up to 2033

Potential for Orphan Drug Exclusivity for IPF and other orphan indications and proprietary implications (eg. Lymphedema)

Pirfenidone approved for IPF and has breakthrough designation for uILD

Clinical validation based on multiple investigator sponsored trials with pirfenidone

Pirfenidone validates efficacy of an anti-inflammatory and anti-fibrotic agent

LYT-100 showed favorable PK to pirfenidone

LYT-100 showed anti-fibrotic and anti-inflammatory activity

LYT-100 | DEUPIRFENIDONE – New Chemical EntityPIRFENIDONE

0

20000

40000

60000

80000

100000

120000

LYT-100 at same dose, 100mg/kg

Pirfenidone 100mg/kg

Control

Plas

ma

TNFα

con

cent

ratio

n 90

m

inut

es o

f ora

l pre

trea

tmen

t, pg

/mL

16

Wholly Owned LYT-100 has potential to address a range of inflammatory and fibrotic conditions

171Cormier et al., Cancer 2010;116(22):5138-49; 2Hayes et al.,Gynecol Oncol. 2017;146(3):623-629; 3Ridner et al., Lymphat Res Biol. 2016;14(4):198-205; 4 Noble et al., European Respiratory Journal 2016;47: 243-253.; 5 Cho et al., 20017, CJASN

Secondary lymphedema occurs in breast cancer and other cancer patients1, including gynecological and head and neck cancer patients2,3

Primary lymphedema includes rare, pediatric lymphatic diseases

Proprietary, preclinical POC

Clinical validation based on multiple

investigator sponsored trials with pirfenidone

Focal segmental glomerulosclerosis (FSGS);Radiation-induced fibrosis

Validation for LYT-100 or pirfenidoneIndications

~130k

~1M

in the United States withIPF or uILD

in the United States overall with lymphedema

Other Fibrotic & Inflammatory Disorders

Idiopathic pulmonary fibrosis (IPF);Unclassifiable interstitial lung disease (uILD);Serious respiratory complications following COVID-19

Clinical/approved

0

50

100

150

0 1 2 3 4 5 6

Chan

ge in

tail

volu

me,

m

m3

Time in weeks

Control LYT-100 Treatment

begins

Lymphedema

IPF4

FSGS5

LYT-100 development plan overview

2020: Initiated Phase 1b study

Multiple ascending dose study and food-effect study in healthy volunteers

• Safety & tolerability

• Pharmacokinetics (PK)

Phase 1b data in 2020

Acute toxicity

ADME

CMC and cGMP clinical supply

In silico PK modeling

Single dose crossover study in healthy volunteers

• Validated patient reported outcomes measuring:

‒ Physical functioning‒ Limb heaviness, pain, and tightness‒ Quality of life impact

• Bioimpedance spectroscopy

• Tonometry (fibrosis)

• Serum inflammatory biomarkers

• Relative limb volume

Exploratory Endpoints

Completed

Patient proof-of-concept and biomarker study in breast cancer-related, upper limb secondary lymphedema

18

2020: Expected POC initiation in lymphedema

Exploring additional fibrotic & inflammatory indications

Q3 2020: Expected POC initiation in post-COVID-19

LYT-100 for serious respiratory complications following resolution of COVID-19 infection

191Cell. 2016 Sep 8;166(6):1485-1499; Nat Med 23, 556–567 (2017).

• Targeting solid tumors with historically low rates of survivaland lack of therapies

• Reverse the immuno-suppressed tumor micro-environment to allow for potent immune-mediated cancer attack

• Galectin-9 and pathogenic γδ1 T cells in tumors correlate with aggressive disease features and lower efficacy of checkpoint inhibitors1

• Demonstrated single agent activity

‒ Demonstrated tumor reduction in preclinical models, including a pancreatic model where anti-PD-1s don’t work, as well as T cell activation in human tumor organoids

• Potential biomarker opportunities for patient selection

>50KMetastatic colorectal cancer

>28KMetastatic pancreatic cancer

>4KMetastatic cholangiocarcinoma

New US patients annually

LYT-200 & LYT-210: Fully human mAbs targeting galectin-9 & immunomodulatory γδ1 T cells in immunologically silent tumors

Wholly Owned

PureTech is executing and delivering results…

20

Since July 2018, PureTech and its Founded Entities have delivered:

11clinical stage trial

initiations

12clinical readouts

7 publications

2 FDA clearances& 2 European CE marksMultiple

strategic partnerships

>$880M raisedwith top-tier

co-investors in Founded Entities

EndeavorRx™

Relative Value of Karuna (KRTX) Stake to PureTech (PRTC) Market Cap

…but these value driving successes have significantly outpaced market capitalization

21

1 This figure represents the stage of development for each Founded Entity’s most advanced product candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representation to the entities’ board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Where PureTech maintains control, the entity is referred to as a Controlled Founded Entity in this report and is consolidated in the financial statements. Where PureTech does not maintain control, the entity is referred to as a Non-Controlled Founded Entity in this report and is not consolidated in the financial statements. As of 31 December 2019, Controlled Founded Entities include Alivio Therapeutics, Inc., Follica, Incorporated, Entrega, Inc., Vedanta Biosciences, Inc. and Sonde Health, Inc., and Non-Controlled Founded Entities include Akili Interactive Labs, Inc., Gelesis, Inc., Karuna Therapeutics, Inc., Vor Biopharma Inc. and, for all periods prior to December 18, 2019, resTORbio, Inc. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of 31 December 2019 (with the exception of Gelesis ownership which is as of 1 April 2020), including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuantto equity incentive plans. Ownership of Vor (calculated as of June 30, 2020) and Sonde is based on the assumption that all future tranches of their most recent financing rounds are funded. Karuna ownership is calculated on an outstanding voting share basis as of 26 May 2020.

Value Components of Other Assets

Founded Entities1

78.3% Equity+ Royalties

Phase 3 Ready

22.0% Equity+ Royalties

FDA Cleared,CE Mark

53.3% Equity Phase 2 78.6% Equity Preclinical 45.9% Equity Phase 1

72.9% Equity Preclinical

34.4% Equity FDA Cleared,CE Mark

11.8% Equity Preclinical

Wholly Owned Pipeline

Source: Management and Capital IQ market data as of June 13, 2020.Phase 1 Preclinical Preclinical

Royalties Only

LYT-100 LYT-200/210

Implied Value

of Other Assets

$--

$200

$400

$600

$800

$1,000

$1,200

Jul-19 Aug-19 Sep-19 Oct-19 Nov-19 Dec-19 Jan-20 Feb-20 Mar-20 Apr-20 May-20 Jun-20 Jul-20

PRTC Market Cap

PRTC Stake in KRTXKRTX

Phase 2 Clinical Trial Success

PRTC sells 2.1M shares

of KRTX

Market peak prior to global

COVID-19 sell-off($M)

Cash

18.1% Equity (KRTX)

End-of-Phase 2 meeting, Initiation of Phase 3 program, add’l. readouts

Numerous milestones expected, including at least 6 readouts and 10 initiations in 2020

22*Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of December 31, 2019 (with the exception of Gelesis ownership which is as of April 1, 2020), including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Ownership of Vor (calculated as of June 30, 2020) and Sonde is based on the assumption that all future tranches of their most recent financing rounds are funded. Karuna ownership is calculated on an outstanding voting share basis as of May 26, 2020.

ProductCandidate

Topline results from multiple clinical studies

Additional strategic partnerships

New clinical candidate selections

Progress of discovery/preclinicalprograms

PureTechOwnership* 2020 2021

LYT-200

Discovery programs

ALV-306

ENT-100

LYT-100

LYT-210

100%

100%

78.6%

72.9%

100%

Nomination of preclinical candidate(s)

Continued advancement of platform

Results from Phase 1b MAD & initiation of POC study in patients

Sonde 45.9% Readout from depression detection study

Preclinical and biomarker studies

IND filing; Initiation of Phase 1 study in solid tumors

100%

VOR33 11.8% Pre-IND meeting with the FDA

KarXT 18.1%

GS500

Plenity®

22.0% Initiation of Phase 3 study in chronic constipation

US limited commercial launch22.0%

AKL-T01 34.4% FDA cleared & European CE Mark granted in pediatric ADHD

FOL-004 78.3% End-of-Phase 2 meeting, Initiation of Phase 3 program in AGA

VE303 53.3% Results from Phase 2 study in high-risk CDI

VE202 53.3% PK/PD results from Phase 1 healthy subject studies for IBD

GS300 22.0% Initiation of Phase 2 study in NASH/NAFLD

LYT-100 100% Initiation of COVID-19 post-recovery respiratory complications study

Results from POC study in patients with breast cancer related lymph

IND filing; Initiation of clinical study in distal colitis & pouchitis

Broad US commercial launch

Results from COVID-19 post-recovery respiratory complications study

GS200 22.0% Results from Phase 2 study in patients with T2D and pre-diabetes

2022

ALV-107 78.6% IND filing

GS100 22.0% Initiation of Phase 2 weight management study in adolescents

VE416 53.3%

VE800 53.3%

Results from Phase 1/2 study in food allergies

Results from Phase 1 study in solid tumors

Initiation of Phase 2 study

indicates completed milestoneKey milestones are bolded

Product candidate related to the BrainProduct candidate related to the Immune systemProduct candidate related to the Gut

Indicates partially completed milestone

B

Results from Phase 1 study

Results from non-human primate POC study, Publishing key preclinical data

Initiations of second Phase 3 study; Open-label study on long-term safety

Initiation of Phase 1 study in acute myeloid leukemia

23

1PureTech Level Pro-Forma Cash Reserves is an alternative performance measure (APM) which includes the PureTech Level Cash Reserves of $120.6 million and the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares. PureTech Pro-Forma Cash Reserves is therefore considered to be more representative of the Corporate’s cash available for the year 2020 and beyond to advance product candidates within the full breadth of its operations; 2$44.5 million in proceeds from the 22 May 2020 sale of 555.5 thousand Karuna common shares.; 3PureTech Level Cash Reserves represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $112.0 million for the year ended 2019 and the internal pipeline of $8.6 million for the year ended 2019, all of which are wholly-owned entities of PureTech, excluding cash balances and short-term investments of Controlled Founded Entities. The balance excludes the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares.

LSE Main Market / FTSE-indexed: PRTCMarket capitalization ~$939M (£758) as of June 30, 2020; 1.24 USD:GBP

Jefferies International Peel Hunt LLP Liberum

Peter Welford Amy Walker Alistair Campbell

Analyst Coverage

Headquartered in Seaport, Boston

$321.5M Pro-forma Cash Reserves at PRTC Parent Level1$45M Cash from KRTX Equity Sale on May 25, 20202

$120.6M Cash Reserves at PRTC Parent Level as of December 31, 20193

285,512,461 outstanding shares as of July 1, 2020

Board & Management

Disclosed Shareholders

Other Shareholders

Disclosed Shareholders as of March 31, 2020 include: Invesco Asset Management Limited, Baillie Gifford & Co., Jupiter Asset Management Ltd., Canaccord Genuity Wealth Management, and M&G Investment Management, LTD.

~11%

~29%

~60%

PureTech is executing and delivering results

24

Partnerships

FDA Clearance &European CE Mark (Gelesis100)

Regulatory

Financings

R&D and data presentations

Akili’s partnership with ShionogiUp to $20M in upfront payments with the potential to receive milestone payments for Japan and Taiwan commercialization of up to an additional $105M in addition to royalties on product sales

Alivio’s partnership with Imbrium TherapeuticsUp to $14.75M in upfront and near-term license exercise payment & eligible to potentially receive $260M+ in research and development milestones in addition to royalties on product sales

Gelesis’ partnership with Ro to support US commercialization of Plenity® Phase 2 results for Karuna’s KarXT Phase 1 results for Vedanta’s VE303 & VE202 Topline results for Follica in AGA Pivotal data for Gelesis100 published in Obesity Pivotal data for AKL-T01 ADHD study published in Lancet

Digital Health Results for Akili’s AKL-T01 in children with ADHD alone or

as an adjunct to stimulants Akili’s AKL-T03 data on MDD presented at ACNP Vedanta’s IO candidate selected and being advanced

with BMS Vedanta’s Nature publication for its IO candidate, VE800 PureTech programs published in Nature and Nature

Neuroscience POC study for Vor published in PNAS Presentations on PureTech’s LYT-200 and LYT-210 at

AACR & SITC

Karuna’s $124M Series A+B financings; $103M IPOKey investors include ARCH Venture Partners, Fidelity, Eventide, Pivotal bioVenture Partners, Partner Fund

Akili’s $68M Series C financingKey investors include Temasek, Amgen Ventures, JAZZ, M Ventures

Vor’s $153M Series A+B financingsKey investors include RA Capital Management, Fidelity Management & Research Company, Pagliuca Family Office, Alexandria Venture Investments,5AM Ventures, Johnson & Johnson Innovation—JJDC, Inc. (JJDC), Osage University Partners, Novartis Institutes for BioMedicalResearch

Vedanta’s $71M Series C financingKey investors include Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital

Sonde’s $16M Series A financingKey investors include M Ventures, MP Healthcare Venture Management, Neoteny 4

Gelesis’ $85M in new capital to support commercialization of Plenity®

Consists of $63.4M financing round led by Vitruvian Partners and $21.2M in new, non-dilutive grant funding and loans

EndeavorRx™ (AKL-T01)

Wholly OwnedPureTech’s track record of success, set to be repeated through our Wholly-Owned Pipeline

25

Initiation of POC study in 2020LYT-100Deupirfenidone Lymphatic flow disorders, incl. lymphedema

LYT-100Deupirfenidone

COVID-19 post-recovery respiratory complications

LYT-210Anti-Delta-1 MAb GI autoimmunity

LYT-210Anti-Delta-1 MAb Solid tumors

Discovery Preclinical Phase 1 Phase 2 Phase 3

LYT-200Anti-Galectin-9 MAb Solid tumors IND and initiation of Phase 1 study in 2020

OUR PROGRAMS

MENINGEAL LYMPHATICSPlatform

MILK EXOSOMEPlatform

LYMPHATIC TARGETINGChemistry Platform

Orphan & other neurological indications

Initiation of POC study in Q3 2020

LYT-100Deupirfenidone Other fibrotic & inflammatory disorders

in progress

completed

Lymphedema: A chronic progressive disease with no FDA approved therapies

261 Patient image: “A comprehensive overview on the surgical management of secondary lymphedema of the upper and lower extremities related to prior oncologic therapies; Figure 1” by Garza et al., 2017 is licensed under CC BY 4.0. 2. DiSipio et al., 2013, Lancet Oncology

~500K breast cancer survivors with secondary lymphedema

~20% of all new breast cancer patients who undergo surgery2

~1M individuals in the US have lymphedema

including

Current treatment options include compression, physical therapy, and surgery (liposuction, lymphovenous transplant)

A progressive disease with disability, disfigurement, and risks of serious comorbidities1

Injury to the lymphatics blocks fluid flow and creates inflammation and fibrosis

27Patient images: Kataru et al., 2019, Translational Res.

Fluid accumulates, causing inflammation and fibrosis

LYMPHEDEMATOUS ARM

Damaged lymphatics create blocked flow

Surgery and radiation damage

lymphatics

HEALTHY ARM

Normal lymphatics drain fluid from tissue

Fluid pumped from arm through lymphatic vesselsHealthy arm

fluorescent tracer image

Lymphedema fluorescent

tracer image

Lymphedema: A feedback loop between inflammation and fibrosis

1Rockson et al., 2019, Nat Rev Dis Primer.; 2Gousopolos et al., 2016, JCI Insight – CD-45 stain.; 3Avraham et al., 2010; Am J Pathology – TGF-β stain

Fibrosis in arm tissue impairs flow and blocks regeneration3

Immune cell infiltration in arm promotes fibrosis2

CD45 stain

Control

Lymphedema

TGF-β stain

A healthy lymphatic system drains interstitial fluid

Damaged lymphatics fail to drain

Healthy lymphatics maintain fluid homeostasis1

28

Preclinical model mimics human pathophysiology and tissue changes

291Ly et al., 2017, Int. J. Mol. Sci.; 2Zampell et al., 2012, PLoS One.; 3Rutkowski et al., 2006, Microvasc Res.

Fibrosis and collagen deposition3

Immune cell infiltration in affected tissue2

Mouse tail lymphatics Lymphatic damage blocks flow1

Lymphedema Control

CD45

+ce

lls (%

)

p<0.01

0

10

20

30

40

Lymphedematous Tail Tissue Stained for Collagen (blue)

A healthy lymphatic system drains interstitial fluid

Damaged lymphatics fail to drain

Control

Healthy tail lymphatics drain fluid

Fibrotic tissue and tail volume

increase

Lymphedematous tail

0

20

40

60

80

100

120

0 1 2 3 4 5 6

Cha

nge

in ta

il vo

lum

e, m

m3

Time in weeks

Control

LYT-100

Treatment begins

LYT-100 once-daily treatment reduced swelling in preclinical models

1Tail volume ± SEM

Mouse lymphedema model: ablation of tail lymphatics results in chronic tail swelling, inflammation, and fibrosis

– Drug started at 2 weekspost-surgery

– N=7: LYT-100N=7: control carboxymethycellulose (CMC)

Systemic treatment(Q.D. oral gavage; 400 mg/kg/d)

WTWT

Tailsurgery

2 wks

LYT-100control

4 wks

Control LYT-100

2 weeks

6 weeks

2 weeks

6 weeks

LYT-100 reduced tail volume in lymphedema model1

30

In vitro reduction of TGF-β induced soluble collagen production (mouse fibroblasts)

Preclinical plasma concentrations of TNFα with LYT-100 versus control

LYT-100 is designed to address underlying mechanisms of lymphedema

31

36% reduction

LYT-100 reduced TGF-β

induced fibrosis

LYT-100 development plan overview

2020: Initiated Phase 1b study

Multiple ascending dose study and food-effect study in healthy volunteers

• Safety & tolerability

• Pharmacokinetics (PK)

Phase 1b data in 2020

Acute toxicity

ADME

CMC and cGMP clinical supply

In silico PK modeling

Single dose crossover study in healthy volunteers

• Validated patient reported outcomes measuring:

‒ Physical functioning‒ Limb heaviness, pain, and tightness‒ Quality of life impact

• Bioimpedance spectroscopy

• Tonometry (fibrosis)

• Serum inflammatory biomarkers

• Relative limb volume

Exploratory Endpoints

Completed

Patient proof-of-concept and biomarker study in breast cancer-related, upper limb secondary lymphedema

32

2020: Expected POC initiation in lymphedema

Exploring additional fibrotic & inflammatory indications

Q3 2020: Expected POC initiation in post-COVID-19

LYT-100 for serious respiratory complications following resolution of COVID-19 infection

Respiratory complications of COVID-19

1Xie, L. Chest Journal. June 2005.; 2Das, K. Indian Journal of Radiology and Imaging. Vol. 27 2017.

Serious post-acute respiratory complications are an emerging issue for those who survive

Recent publications suggest a high proportion of mild, moderate and severe COVID-19 patients show signs of lung fibrosis at three weeks post symptom onset

In SARS, patients can develop persistent pulmonary fibrosis1

and up to 1/3 of SARS and MERS patients have pulmonary fibrosis after recovery2

Many interstitial lung diseases (ILDs) are characterized by inflammation and fibrosis, which can result in impaired lung function and progressive pulmonary fibrosis

Clinical trials in the post-acute setting are important as millions of people have been infected by COVID-19

33

Rationale

LYT-100 for serious respiratory complications following resolution of COVID-19

341 Spagnolo, P. The Lancet May 2020

Trial Design

Global, randomized, placebo-controlled trial will evaluate LYT-100 in non-critical COVID-19

patients with respiratory complications

N = approximately 150

Topline results expected mid-2021

LYT-100 showed anti-fibrotic and anti-inflammatory activity

0

20000

40000

60000

80000

100000

120000

Plas

ma

TNFα

con

cent

ratio

n 90

m

inut

es o

f ora

l pre

trea

tmen

t,

pg/m

L

LYT-100 at same dose, 100mg/kg

Pirfenidone 100mg/kg

Control

LPS Model (Rats), n=6-8 per group, 100mg/mL

Pirfenidone mechanisms in acute and chronic interstitial lung diseases

• Reduces pro-inflammatory cytokines: IL-6, TNF-α

• Suppresses TGF-β and downstream signaling

Primary outcome

• Pulmonary function testing

Secondary endpoints

• Safety and tolerability

• Pharmacokinetics

• Acute inflammatory biomarkers

• Hospitalization events

• Imaging and patient reported outcomes

Multimodal mechanism of action

LYT-100 for focal segmental glomerulosclerosis (FSGS)

351Sim et al., 2016, Am J Kidney Dis.; 2Cho et al., 2007, CJASN. Image: (L) Chiang & Inagi, 2010, Nat Rev Nephrol; (R) Stokes et al., 2006, Kidney International

• Rare, progressive fibrotic kidney disease that can lead to kidney failure and dialysis1

‒ 4,500 to 8,000 individuals develop FSGS every year

• Clinical proof of concept with pirfenidone in FSGS demonstrated in NIH study (N=21)2:‒ 25% median improvement in

the rate of decline of glomerular filtration rate

‒ Projected renal survival prolonged by ~55%

• No specific treatments designed to reduce fibrosis and inflammation

• Current treatment with immunosuppression is symptomatic and often ineffective in preventing relapse and progression to end-stage renal disease

• LYT-100 has favorable PK over pirfenidone which enables lower dosing and potentially improved safety

Segmental lesion in FSGS

361Cell. 2016 Sep 8;166(6):1485-1499; Nat Med 23, 556–567 (2017).

• Targeting solid tumors with historically low rates of survivaland lack of therapies

• Reverse the immuno-suppressed tumor micro-environment to allow for potent immune-mediated cancer attack

• Galectin-9 and pathogenic γδ1 T cells in tumors correlate with aggressive disease features and lower efficacy of checkpoint inhibitors1

• Demonstrated single agent activity

‒ Demonstrated tumor reduction in preclinical models, including a pancreatic model where anti-PD-1s don’t work, as well as T cell activation in human tumor organoids

• Potential biomarker opportunities for patient selection

>50KMetastatic colorectal cancer

>28KMetastatic pancreatic cancer

>4KMetastatic cholangiocarcinoma

New US patients annually

LYT-200 & LYT-210: Fully human mAbs targeting galectin-9 & immunomodulatory γδ1 T cells in immunologically silent tumors

Wholly Owned

Foundational biology:

Proof-of concept in preclinical models:

LYT-200: Aimed at galectin-9, a fundamental modulator of the immune system

37Image adapted from J Mol Biol; 428 (16): 3266-3281; 2016Treg = T regulatory cell; MDSC = myeloid derived suppressor cell; M1/M2 = tumor associated macrophage (TAM)1 (immunoactive) and 2 (immunosuppressed) cell; Th1 = T helper1 cell*CPI=checkpoint inhibitor

Affects multiple pathways of immunosuppression, potentially enabling a single-agent therapeutic

Promotes expansion of

MDSCs

Induces Treg cell differentiation

and stability

Induces apoptosis of Th1 and

CD8+ T cells

Treg

CD8

Th1

MDSCs

CD8

Tumor

Galectin-9

Switching M1 to M2 macrophage

M1 M2

A model where anti-PD1s do not work

T cell activation with LYT-200 in patient-derived organoid model

Single agent activity in KPC (pancreatic cancer) model

T cell activation with LYT-200 in patient-derived organoid model1

Multiple lines of preclinical data supporting therapeutic potential of LYT-200

381For patient-derived organoids, n = 20 tumor samples; Success defined as: >20% upregulation of at least two out of three T cell activation markers; success achieved in 60% of tumors with majority showing >2 fold activation

n = 10 / armP < 0.01

800

600

400

200

Tum

or w

eigh

t (m

g)LYT-200 drug properties make it an

excellent clinical clone:

• High affinity and specificity for galectin-9

• Desired function: Blocking galectin-9 mediated immunosuppression

• Robust activity in preclinical studies:‒ Single agent causes tumor reduction in

pancreatic and melanoma mouse models

‒ Observed ~50% tumor reduction with LYT-200 vs. ~22% tumor reduction with anti-PD1 in melanoma model

‒ Increase in intra-tumoral CD8 T cells in combination with anti-PD1

‒ Activation of intra-tumoral immunity in patient-derived tumor models

A model where anti-PD1s do not work

Dose escalation and dose expansion study Clinical Investigators

Planned LYT-200 Phase 1 study design for metastatic solid tumors

39

Dose finding (all comers), safety, tolerability, RP2D, PK/PD

Further expansion aimed at enabling accelerated approval single agent and/or combo

Safety and efficacy– exploratory endpoints –

Pancreatic Colorectalcholangiocarcinoma

Other amenable GI/non-GI indications

Filip Janku Osama Rahma

Aparna Parikh

Richard Carvajal

Zev Wainberg

Neil Segal

Manji Gulam

Brian Wolpin

2nd Clinical Advisory Board held at ASCO 2019

LYT-210: Monoclonal antibody aimed at immunosuppressive γδ1 T cells

40Image adapted from CellPress: REVIEW: γδ T Cells: Unexpected Regulators of Cancer Development and Progression. DC = dendritic cell; TAM = tumour associated macrophage; MDSC = myeloid derived suppressor cell; IL17 = interleukin 17

Immunosuppressive γδ1 T cells

Solid tumors harbor immunosuppressive γδ1 T cells that correlate with tumoraggressiveness / lower rate survival

LYT-210 is a fully human monoclonal IgG1 antibody (cross reacts with monkey)

Works through multiple pathways to cause immunosuppression in the tumor micro-environment

Pro-tumor γδ1 T cells

Restrict cytotoxic γδ T cells activity

Chemoattract MDSCs, TAMs neutrophils

Immunosuppressive cytokine production (exp. IL17)

Restrict and suppress cytotoxic αβ T cell activity

TUMOR PROGRESSION

Inhibit maturation and antigen presentation of DCs

Multiple lines of preclinical data supporting therapeutic potential of LYT-210

411For patient-derived organoids: Analyzed n = 22 tumor samples; success defined as: >20% upregulation of at least two out of three T cell activation markers; Success achieved in 63% of tumors with majority showing >2-fold activationCell. 2016 Sep 8;166(6):1485-1499 ; * Tool antibody that blocks mouse immunosuppressive γδ T cells

Single agent activity in KPC (pancreatic cancer) model

(Published in Cell)T cell activation with an anti-δ1 mAb in

patient-derived organoid model1

n = 10 / armP =0.009

%IF

Nγ+

(CD8

+ T c

ells

)

15

0

5

10

%TF

N⍺+

(CD8

+ T c

ells

)

15

0

5

10

LYT-210 candidate clone has excellent drug properties:

• High affinity and specificity/ selectivity for pathogenic γδ1 T cells

• Species cross reactivity to enable IND tox

• Desired function: Inducing ADCC/ ADCP and activating suppressed effector T cells in patient-derived tumor models

• Proof of principle in animal models:‒ Targeting immunosuppressive γδT

cells significantly prolongs survival in a KPC model

‒ Targeting immunosuppressive γδT cells synergizes with checkpoint inhibitors in melanoma and lung cancer models

• A Phase 2 study of KarXT for schizophrenia met the primary endpointwith a statistically significant (P<0.0001) and clinically meaningful 11.6 point improvement on the PANSS total score from baseline vs. placebo

• KarXT was well-tolerated in the Phase 2 trial, with similar discontinuation rates between KarXT and placebo

• Xanomeline, exclusively licensed from Eli Lilly, previously demonstrated dose-dependent decreases in multiple psychotic symptoms and related behaviors in schizophrenia and Alzheimer’s disease patients, as compared to patients on placebo

• Potential to target additional indications, including dementia-relatedpsychosis and pain

Karuna: Selectively activating muscarinic acetylcholine receptors in the brain

42*As of May 26, 2020, PureTech’s percentage ownership of Karuna was approximately 18.1 percent on an outstanding share basis. PureTech Health has a right to royalty payments as a percentage of net sales from Karuna.

KarXT

Positive outcome of End-of-Phase 2 meeting with FDA; initiation of Phase 3 program by end of 2020

Key Highlights

• KarXT is a selective muscarinic receptor agonist for the treatment of psychosis and cognitive impairment across CNS disorders

XanomelineCNS active agonist

Trospium chloride Peripheral antagonist blocks side effects of agonist

Muscarinic agonist

Muscarinic antagonist

~2.7Mliving with schizophrenia in the US

Current antipsychotics in use all rely on the same fundamental mechanism of action

At least half of patients fail to adequately respond to current antipsychotics, with others discontinuing medication due to severe side effects, including sedation, extrapyramidal side effects and significant weight gain

PRTC Ownership: 18.1%*

KarXT Phase 2 primary endpoint: PANSS Total Score at week 5, and topline results

Source: Karuna Phase 2 results from company presentation

• Clinically meaningful and statistically significant improvement in total PANSS vs. placebo, with 11.6 point improvement at Week 5 with p<0.0001

• Statistical separation at every assessed time point

• Statistically significant reduction in the secondary endpoints of PANSS-positive and PANSS-negative subscales at all assessed timepoints

• The overall discontinuation rate and the discontinuation rate due to treatment emergent adverse events on KarXT was similar to placebo

• 91% of patients escalated to the high dose of KarXT as part of the flexible dose design

• No evidence of somnolence, extrapyramidal side effects, or weight gain

43

Karuna pipeline and upcoming milestones

Product candidate Indication Discovery/Preclinical Phase 1 Phase 2 Phase 3 Upcoming

Milestone

KarXT

Schizophrenia – psychosisPhase 3 study

initiation by end of 2020

Schizophrenia – cognitive symptoms Phase 1b study initiation H1 2020

Schizophrenia – negative symptoms Phase 1b study initiation H1 2020

Dementia-related psychosis Phase 1b topline data end of 2020

Pain Phase 1b topline data mid-2020

Other Muscarinic-targeted drug candidateIND-enabling

studies2020

Phase Completed

Phase In-progress 44

Gelesis: FDA-cleared for the broadest patient population of any weight management aid

45

*As of 1 April 2020, PureTech’s percentage ownership of Gelesis was approximately 22.0 percent on a diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans and assumes all committed tranches are funded in the Series 3 Growth financing round. PureTech has a right to royalty payments as a percentage of net sales from Gelesis.; 1Important Safety Information: Plenity is contraindicated in patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide. Plenity may alter the absorption of medications. Read Sections 6 and 8.3 of the Instructions for Use carefully. Avoid use in patients with the following conditions: esophageal anatomic anomalies, including webs, diverticuli, and rings; suspected strictures (such as patients with Crohn’s disease); or complications from prior gastrointestinal (GI) surgery that could affect GI transit and motility. Use with caution in patients with active GI conditions such as gastro-esophageal reflux disease (GERD), ulcers or heartburn. The overall incidence of adverse events (AEs) in the Plenity group was no different than the placebo group. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. For the safe and proper use of Plenity, refer to U.S. Instructions for Use or the EU Instructions for Use.

Key Highlights• Plenity is FDA-cleared for the broadest

patient population of any weight management product (BMI 25-40 kg/m2)

• Granted European CE mark to market Plenity as a class III medical device

• Differentiated risk/benefit profile• Consumer-driven approach enabled by

unique risk benefit profile, unlike any previously launched obesity drug

• Partnership with Ro to support US commercialization of Plenity

• Proprietary mechanically-acting hydrogel platform, made from naturally-derived building blocks

Plenity®1, GS100, Gelesis200, GS300, GS400, GS500

Broad US launch of Plenity anticipated in 2021

PRTC Ownership: 22.0%*

Other prescribed therapeutics for obesity are systemically and centrally acting with potential for serious safety concerns, greatly limiting their use

~150MIndividuals in the US with overweight and obesity within Plenity’s label

Consumer expectations for weight loss provide an opportunity for Plenity® in target population of BMI <35

461 Shannon K, et.al,. Obesity disease coverage. Datamonitor Healthcare report 2017:56-59; 2 Based on KOL and clinical experience.; Note: Placement of treatment logos reflects the BMI where most usage occurs – not the FDA indication or label

Current Rx options have safety and tolerability challenges

So, they are reserved for highest risk high BMI patients (60% of use in

24% of the population)1

The weight loss they offer is not generally satisfying for higher

BMI patients2

Patient/Physician Willingness to Accept Safety RiskLow Higher

BMI 25-27 BMI 27-30 BMI 30-35 BMI 35-40 BMI >40

>75% of adults affected with

Overweight/Obesity

19M

33M

50M47M

23M

(Gelesis100)

US PopulationPlenity’s Target

Hope to lose 15 – 30 LBS

Plenity meets consumer expectations

Hope to lose >40 LBS Current therapies don’t meet

consumer expectations

Key findings from Plenity® pivotal study

47TEAE = Treatment Emergent Adverse Event; For the safe and proper use of Plenity, refer to the Instructions for Use in the US and EU.

RESPONDERSADULTS ACHIEVING 5% OR GREATER WEIGHT LOSS

SUPER RESPONDERSADULTS ACHIEVING 10% OR GREATER WEIGHT LOSS

• 59% of adults with overweight or obesity had a clinically meaningful response to Plenity®, losing on average 10% of their weight (22 pounds) or ~3.5 inches from their waist

• Plenity doubled the odds of achieving 5% or greater weight loss compared with placebo

• 26% of adults with overweight or obesity were super-responders to Plenity, losing on average 14% of their weight (30 pounds)

6 out of 10

26%Co-primary endpoint – The study also demonstrated statistically superior weight loss compared with the placebo group (−6% vs −4%, respectively; P=0.0007) and did not meet the predefined super-superiority margin of 3%

Safety – Plenity had no overall increased risks versus placebo, no serious adverse events and a lower dropout rate versus placebo

Most common side effects are fullness, bloating, flatulence, and/or abdominal pain

Plenity (n) Placebo (n)

% of subjects with severe TEAE 3.6% (8) 4.7% (10)

# of subjects with serious TEAE 0 1*

Plenity go-to-market approach

48Important Safety Information: Plenity is contraindicated in patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide. Plenity may alter the absorption of medications. Read Sections 6 and 8.3 of the Instructions for Use carefully. Avoid use in patients with the following conditions: esophageal anatomic anomalies, including webs, diverticuli, and rings; suspected strictures (such as patients with Crohn’s disease); or complications from prior gastrointestinal (GI) surgery that could affect GI transit and motility. Use with caution in patients with active GI conditions such as gastro-esophageal reflux disease (GERD), ulcers or heartburn. The overall incidence of adverse events (AEs) in the Plenity group was no different than the placebo group. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. For the safe and proper use of Plenity, refer to U.S. Instructions for Use or the EU Instructions for Use.

Lower barrier to access by both driving telehealth and traditional physician visits while leveraging mail order to create an Amazon-like experience

A support program that encourages diet, exercise, mindful eating, plus packaging that fits into lifestyle

Directly tap consumer demand via targeted digital engagement and influencer focus1 Patients drive

demand of

2 Strong base of physicians ready to

prescribe via telehealth

3 Member-centric customer experience

Gelesis pipeline and upcoming milestones:

*Products are investigational and have not been cleared by the FDA for use in the United States.; **Contingent on FDA review of the research plan.

Product candidate Indication Discovery/Preclinical Phase 1 Phase 2 Phase 3 FDA

ClearanceUpcoming Milestone

Plenity®

(GELESIS100) Weight management in overweight and obese patients

Broad US launch 2021

GS100* Weight management in adolescent overweight and obese patients

Phase 2 study initiation2021**

GELESIS200* Weight management and glycemic control in patients with T2D and pre-diabetes

Phase 2 study topline data 2021

GS300* NAFLD / NASHPhase 2 study

initiation2020**

GS400* Mucositis / IBD

GS500* Chronic Constipation (CIC) Phase 3 study initiation 2020**

Cleared by FDAEuropean CE mark granted

Phase Completed

Phase In-progress

Mechanical properties regenerating gut barrier and other mechanisms have led to compelling preclinical and clinical data in additional indications (e.g., NASH/NAFLD, CIC, and IBD)

49

Follica: Growing new hair based on innovative findings in regenerative biology

50*PureTech Health has a right to royalty payments as a percentage of net sales from Follica. As of 31 December 2019, PureTech’s percentage ownership of Follica was approximately 78.3 percent on a diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans.

• Proprietary in-office treatment combines targeted scalp micro-disruption device with a topical on-market drug to create and grow new hairs

Follica Platform

PRTC Ownership: 78.3%*

~90MTotal addressable

population of androgenetic alopecia (AGA) sufferers Key Highlights

• Follica is developing an in-office treatment to grow new hair in patients with AGA, a large, cash-pay, unaddressed multi-billion market

• Selected treatment regimen demonstrated 44% improvement of visible hair count over baseline

• Attractive physician practice economics consistent with in-office aesthetic procedures

• Strong IP and proprietary device create high barriers to entry and protect against off label use

• Significant future growth opportunities: female pattern hair loss, skin rejuvenation, and proprietary amplification compounds

Follica is developing a treatment for a condition unresolved today, unlocking a multi-billion market of unmet need

Planned initiation of Phase 3 program in 2020

Currently-approved treatments work with only the hair you already have, either transplanting existing hair, or reviving shrunken hair folliclesFollica is the first company to grow new hair

Broad range of individuals with hair loss (e.g., age, severity, income levels) have significant interest in a more effective option

Even in the absence of effective treatment options, the AGA market today is $1B+ in the US and $3.5B globally

Sample patient outcome from FOL-004 data

Note: Results depicted in the images are above the average demonstrated in the optimization trial.

• Follica is developing an approximately five-minute in-officeexperimental procedure associated with limited downtime

• Follica’s approach is comprised of a proprietary device designed to stimulate hair follicle growth, followed by treatment with a pharmaceutical compound to thicken and maintain newly created hair follicles

• Follica’s selected treatment regimen demonstrated a statistically significant 44% improvement of visible (non-vellus) hair count after three months of treatment compared to baseline (p < 0.001, n=19)

• A prespecified analysis comparing the 44% change in non-vellus hair count to a 12% historical benchmark with approved pharmaceutical products was statistically significant (p = 0.005)

• Blinded head-to-head bench testing of the proprietary Follicadevice has shown advantages in scalp treatment versus commercially available skin disruption devices

• Initiation of Phase 3 registration program is anticipated in 2020

51

Day 85Screening

Akili: First game-based digital therapeutic cleared by the FDA for ADHD

52*As of 31 December 2019, PureTech’s percentage ownership of Akili was approximately 34.4 percent on a diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant toequity incentive plans.

EndeavorRxTM (AKL-T01), AKL-T02, AKL-T03, AKL-T04

~6.4MPediatric ADHD patients in the US

FDA cleared for pediatric patients age 8 to 12 years old with primarily inattentive or combined-type ADHD who have a demonstrated attention issue

Key Highlights• First game-based digital therapeutic cleared by the FDA for ADHD or any type of

condition. Providing a non-drug approach to target cognitive challenges

• Granted CE Mark to market EndeavorRx in European Economic Area member countries

• Novel mode of activating neural systems in the brain

• EndeavorRx (AKL-T01) met primary endpoint in double-blind, placebo-controlled pivotal study for pediatric ADHD (with active comparator game), and recently showed statistically significant improvement in ADHD Impairment Rating Scale (IRS), when used alone and as adjunct to stimulants

• AKL-T03 achieved primary endpoint, improving cognitive impairments in major depressive disorder trial

• Commercial and development partnership with Shionogi in Japan and Taiwan

• Potential to target cognitive impairments in other indications: ASD, MDD, MS, MCI, and TBI

• Personalized digital therapeutics engineered to directly improve cognitive and attention impairments

• Delivered through immersive action video game experience

PRTC Ownership: 34.4%*

The treatment of many neuropsychiatric disorders is only partially served, or not served at all, by currently available medications or by in-person behavioral therapy

Achieved primary endpoint in pivotal study for pediatric ADHD

531Kollins, et. al., The Lancet Digital Health. 2020 Apr. 2: e168–78. SE: Standard Error

• Achieved primary endpoint in randomized, controlled pivotal study for AKL-T01 in pediatric ADHD in Q4 2017

• AKL-T01 showed statistically significant change in the Attention Performance Index on T.O.V.A.®, an FDA-cleared objective measure of sustained attention and inhibitory control, compared to active control (p=0.006)

• Improvements in behavioral symptoms and functional impairments, though not separated from control

• No serious adverse events or discontinuations

Tests of Variables of Attention (T.O.V.A.), FDA-cleared ADHD treatment monitor

The Lancet Digital Health, 20201

Akili pipeline

1 Davis et al., PLoSONE. 2018, 13(1):e0189749. Kollins et al., JAACAP. 2018 Oct. V57(10) S172. NCT02828644. No data published yet. NCT03649074. On-going. NCT03844269. On-going.; 2 Yerys et al. Journal of Autism and Developmental Disorders. 2018 Dec. 3 Anguera et. al. Depression and Anxiety. Jan. 2017

Phase Completed

Phase In-progress

Product candidate Indication Discovery/Preclinical

Phase 1 (Feasibility)

Phase 2 (POC)

Phase 3(Pivotal)

FDA Clearance

Behavioral

EndeavorRxTM

(AKL-T01) Pediatric ADHD1

AKL-T02 Pediatric autism2

Mood & affective

AKL-T03 Major depressive disorder3

AKL-T04 Major depressive disorder

Immune AKL-T03 Multiple sclerosis

OtherAKL-T01 Parkinson’s / MCI

AKL-T01 Traumatic brain injury

Product candidate Indication In Development Clinical Trials Released

Health care solutions apps AKL-X01 ADHD caregiver app

Cleared by FDAEuropean CE Mark Granted

54

• Four clinical-stage programs in development• VE303, in development for high risk C. difficile,

demonstrated rapid, durable, dose-dependent colonization and accelerated gut microbiota restoration after antibiotics in a Phase 1a/1b study

• VE202, in development for IBD, demonstrated durable and dose-dependent colonization after antibiotics in two Phase 1 studies

• VE800 being evaluated with OPDIVO® (nivolumab) in advanced or metastatic cancers

• Strong IP portfolio

• Defined consortia to shift microbiota, stimulate immune responses, and provide colonization resistance against infectious pathogens

Vedanta: Developing a new class of drugs to modulate the human microbiome

55*As of 31 December 2019, PureTech’s percentage ownership of Vedanta Biosciences was approximately 53.3 percent on a diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans.

Clinical data readout for VE303 expected in 2020

Key Highlights

VE303, VE202, VE416, VE800CDI is typically treated using antibiotics which damage the microbiome, leaving patients vulnerable to re-infection

IBD interventions are limited by toxicities and systemic immune suppression

Treatment centers around allergen avoidance and desensitization therapies in development, which may not prove cost-effective

Checkpoint inhibitors are only effective in 20 – 30% of patients

100 – 120Khigh-risk CDI cases per year

in the US

~3MIBD patients in the US

~2.5MLiving with peanut allergy in the US

>66K/yearMetastatic and/or

advanced MSS CRC, gastric, and melanoma

patients in the US

PRTC Ownership: 53.3%*

Vedanta pipeline and upcoming milestones

Phase Completed

Phase In-progress

Product candidate Indication Discovery/Preclinical Phase 1 Phase 2 Phase 3 Upcoming

Milestone

VE303 High-risk C. difficile (CDI) Phase 2 data readout 2020

VE416 Food allergy Phase 1/2 data readout 2021

VE202 Inflammatory bowel disease Phase 2 initiation 2021

VE800 Cancer immuno-therapy indication Phase 1 datareadout 2021

56

Vor: Selectively protecting healthy cells from targeted cancer therapies

57*As of June 30, 2020, PureTech’s percentage ownership of Vor was approximately 11.8 percent on a diluted basis. Ownership is based on the assumption that all future tranches of their most recent financing rounds are funded.

Key Highlights• Ex vivo and mouse proof-of-concept studies led

by Siddhartha Mukherjee, MD, PhD, published in PNAS

• Designed to optimize targeted therapies including ADCs, T cell engager / bispecific antibodies, and CAR-T cells

• Approach may lead to lower on-target toxicity, enable earlier therapy, and enable chronic dosing of targeted therapies

• Platform broadly applicable to other targets across and beyond heme malignancies

• Engineered hematopoietic stem cells (eHSCs) deleting redundant epitopes, protecting healthy cells from targeted therapies

eHSC Platform~60KAcute myeloid leukemia patients in the US

The prognosis for relapsed and refractory blood-borne malignancies is very poor

Only 30% of AML patients relapsing following stem cell transplants survive beyond one year

Targeted therapies have shown excellent outcomes, but frequently target both cancer and normal cells, causing substantial toxicities and limiting their potential

PRTC Ownership: 11.8%*

Initiation of Phase 1 study in acute myeloid leukemia in 2021

Alivio: Locally-acting therapeutic for devastating GI disease

58*As of December 31, 2019, PureTech’s percentage ownership of Alivio was approximately 78.6 percent on a diluted basis. This calculation includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans.

IND filing expected for ALV-306 in 2021

Key Highlights• Alivio’s platform has been validated in multiple

preclinical models and indications• Technology could be applied to diseases, such

as IBD, pouchitis, inflammatory arthritis, organ transplantations, and IC/BPS

• Proprietary platform that can use small molecules and biologics, with potential for partnership targeting non-GI indications

• Ongoing partnership with Imbrium to advance ALV-107

• Novel technology designed to selectively bind to inflamed tissues and allow for targeted treatment of inflammatory disorders

ALV-306, ALV-304, ALV-107

Current drugs for GI autoimmune conditions focus on symptomatic relief and act systemically, causing toxicity

Pouchitis is a debilitating inflammation of the ileal pouch

Distal colitis represents a subtype of ulcerative colitis for which refractory disease is difficult to manage

~225KIndividuals in the US have

distal colitis

70 – 135KIndividuals in the US have

pouchitis

PRTC Ownership: 78.6%*

Sonde: Voice-based technology with the potential to transform how we monitor health

59*As of December 31, 2019, PureTech’s percentage ownership of Sonde was approximately 45.9 percent on a diluted basis. This calculation assumes all future closings of the Series A financing and includes outstanding shares, options, and warrants, but excludes unallocated shares authorized to be issued pursuant to equity incentive plans.

Sonde

Key Highlights• Launched Sonde One, a voice-enabled health detection and

monitoring app, to potentially help employers reopen offices in COVID-19 environment

• Technology has demonstrated the potential to screen and monitor for disease in individuals from brief samples of speech

• Ongoing collaborations with multiple US and ex-US hospitals, clinics, and academic medical centers

• Collected 300,000 voice samples from over 50,000 subjects as part of ongoing validation of platform

• Expanded development of its proprietary technology in neurodegenerative disease, respiratory and cardiovascular disease, and other health and wellness conditions

• Developing proprietary technology to enable effective disease screening and management solutions based on an analysis of seconds of voice capture through consumer devices

PRTC Ownership: 45.9%*

~17MIndividuals in the US are affected by depression

The lag between onset of disease and accurate diagnosis and beginning of treatment can be measured in years for many high-burden health conditions

Topline results from a depression detection study expected in 2020

Product Candidate Details (1 of 3)

60

* PureTech is not responsible for development of all of these product candidates and FDA-cleared product. Our Non-Controlled Founded Entities and certain of our Controlled Founded Entities, Follica and Vedanta, have independent development teams and PureTech does not control the day-to-day development of their respective product candidates. However, with respect to these Controlled Founded Entities, we exert control through majority stock ownership, board representation, and voting decisions. ** As of 31 December 2019, Controlled Founded Entities include Alivio Therapeutics, Inc., Follica, Incorporated, Entrega, Inc., Vedanta Biosciences, Inc. and Sonde Health, Inc., and Non-Controlled Founded Entities include Akili Interactive Labs, Inc., Gelesis, Inc., Karuna Therapeutics, Inc., Vor Biopharma Inc. and, for all periods prior to December 18, 2019, resTORbio, Inc. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of December 31, 2019 (with the exception of Gelesis ownership which is as of April 1, 2020), including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Ownership of Vor (calculated as of June 30, 2020) and Sonde is based on the assumption that all future tranches of their most recent financing rounds are funded. Karuna ownership is calculated on an outstanding voting share basis as of May 26, 2020. R PureTech Health has a right to royalty payments as a percentage of net sales.

Product Candidate*

PureTech Ownership**

Indication(US Patient Population)

Potential Key Differentiation Results & Milestones Expected milestones

LYT-100 100% (Internal) Lymphatic flow disorders, incl. Lymphedema (~1M),COVID-19 post-recovery respiratory complicationsOther fibrotic and inflammatory disorders

Product candidate for the potential treatment of a range of conditions involving fibrosis, inflammation and impaired lymphatic flow. Pre-clinical anti-fibrotic and anti-inflammatory activity

• Acquired LYT-100 in July 2019 from Auspex Pharmaceuticals • Initiated LYT-100 multiple ascending dose study in March 2020• Presented preclinical data supporting LYT-200 and LYT-210 at AACR

2019• Presented additional preclinical data on LYT-200 and LYT-210 at SITC in

November 2019• Announced issuance of patent covering compositions of matter directed

to fully human anti-galectin-9 antibodies to support LYT-200 in 2019

• Initiation of LYT-100 human proof-of-concept study in people with breast cancer-related, upper limb secondary lymphedema in 2020, as well as additional studies in people with other fibrotic and inflammatory conditions

• Initiation of proof-of-concept study for serious respiratory complications following resolution of COVID-19 in Q3 2020

• Plans to file an IND application and initiate a Phase 1 study in solid tumors for LYT-200 in 2020

• Plans to continue to advance preclinical and biomarker studies for LYT-210 in 2020

LYT-200 Solid tumors, including colorectal (>50K/year), pancreatic (>28K/year), cholangiocarcinoma (>4K/year)

Capacity to concurrently modulate multiple immunosuppressive pathways and deliver significant single agent activity

LYT-210 Solid tumorsGI Autoimmunity

Focused on a therapeutic strategy which is distinct from other interventions using or targeting cytotoxic γδ T cells

ALV-306 78.6%(Alivio)

Pouchitis (70 – 135K), distal colitis (~225K),

Novel technology that selectively binds to inflamed tissues and allows for targeted treatment of chronic and acute inflammatory disorders

• Preclinical study of technology published in Nature Communications in April 2018, with two previous publications in Sci Transl Med

• Technology evaluated in 10 animal models; multiple therapies (small molecules and biologics) successfully incorporated

• $3.3M Department of Defense award• Announced partnership with Imbrium to advance ALV-107; Alivio will

receive up to $14.75M in upfront and near-term license exercise payments and is eligible to receive royalties on product sales and $260M+ in R&D milestones

• Expects to file IND for ALV-306 and initiate clinical trial in pouchitis and distal colitis in 2021

• Expects to file an IND for ALV-107 for IC/BPS in 2021 and an IND for ALV-304 in IBD in 2022

ALV-304 IBD (~3M)

ALV-107 IC/BPS (4 – 12M)

FOL-004 78.3%(Follica) R

AGA (~90M) Pioneering technology focused on the creation of new hair follicles via skin disruption and subsequent treatment to enhance effect

• Continued development to address androgenetic alopecia based on three clinical studies which showed hair follicle neogenesis following skin disruption

• Identified and tested next-generation, proprietary compounds• Announced topline results from a safety and efficacy optimization study of

lead candidate in December 2019• Positive feedback from End of Phase 2 meeting with the FDA for FOL-

004 to treat male AGA

• Initiation of Phase 3 registration study in male androgenetic alopecia is expected in 2020

FOL-005 Skin rejuvenation

Product Candidate Details (2 of 3)

61

* PureTech is not responsible for development of all of these product candidates and FDA-cleared product. Our Non-Controlled Founded Entities and certain of our Controlled Founded Entities, Follica and Vedanta, have independent development teams and PureTech does not control the day-to-day development of their respective product candidates. However, with respect to these Controlled Founded Entities, we exert control through majority stock ownership, board representation, and voting decisions. ** As of 31 December 2019, Controlled Founded Entities include Alivio Therapeutics, Inc., Follica, Incorporated, Entrega, Inc., Vedanta Biosciences, Inc. and Sonde Health, Inc., and Non-Controlled Founded Entities include Akili Interactive Labs, Inc., Gelesis, Inc., Karuna Therapeutics, Inc., Vor Biopharma Inc. and, for all periods prior to December 18, 2019, resTORbio, Inc. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of December 31, 2019 (with the exception of Gelesis ownership which is as of April 1, 2020), including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Ownership of Vor (calculated as of June 30, 2020) and Sonde is based on the assumption that all future tranches of their most recent financing rounds are funded. Karuna ownership is calculated on an outstanding voting share basis as of May 26, 2020. R PureTech Health has a right to royalty payments as a percentage of net sales.

Product Candidate*

PureTech Ownership**

Indication(US Patient Population)

Potential Key Differentiation Results & Milestones Expected milestones

VE303 53.3% (Vedanta)

High-risk CDI (100 – 120K per year) Developing a new category for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria

• Announced successful Phase 1a/1b for VE303 showing VE303 was well tolerated and demonstrated proof of mechanism in healthy volunteers in Q4 2018

• Announced initiation of Phase 2 trial for VE303 in Q4 2018• Raised $71.1M in total Series C financing round• Announced PK/PD results from VE202 Phase 1 healthy subject trials in

Q2 2020• Announced initiation of Ph1/2 trial for VE416 in July 2019• Announced an IO collaboration with BMS to evaluate OPDIVO®

(nivolumab) and VE800 in advanced or metastatic cancers in Q4 2018• Announced initiation of first in patient trial for VE800 in Q4 2019

• Topline results for VE303 Phase 2 expected in 2020

• Topline data from the Phase 1/2 clinical trial of VE416 are expected in 2021

• Topline results from first-in-patient clinical trial of VE800 anticipated in 2021

• Initiate a VE202 Phase 2 study in IBD in 2021

VE202 IBD (~3M)

VE416 Peanut allergy (~2.5M)

VE800 Solid tumors including MSS CRC (>46K/year), gastric (>11K/year), and melanoma (>9K/year)

Sonde 45.9%(Sonde)

Depression detection (~17M) Developing a voice-based technology platform to measure health when a person speaks that is designed to sense and analyze subtle changes in the voice to create a range of persistent brain, muscle, and respiratory health measurements that provide a more complete picture of health in seconds

• Launched Sonde One to potentially help employers reopen offices in COVID-19 environment in July 2020

• Demonstrated accuracy for measuring depression from brief samples of speech

• Expanded development of proprietary technology in neurodegenerative disease, respiratory and cardiovascular disease, and other health and wellness conditions

• Collected 300,000 voice samples from over 50,000 subjects as part of ongoing validation of platform

• Completed $16M financing in Q2 2019

• Topline results from a depression detection study expected in 2020

• Expects to launch its API platform, which will allow the world to license and build products with Sonde’s voice biomarker based health detection technology, in 2020

EndeavorRXTM

(AKL-T01)34.4%(Akili)

Pediatric ADHD (~6.4M) Pioneering the development of treatments designed to have direct therapeutic activity, delivered through a high-quality action video game experience

• EndeavorRxTM (AKL-T01) granted FDA clearance as a prescription treatment for children with attention-deficit/hyperactivity disorder (ADHD)

• CE Mark approval to market EndeavorRx in European Economic Area member countries

• Announced study achieved its primary endpoint evaluating the effects of lead product candidate AKL-T01 in children with ADHD when used with and without stimulant medication in January 2020

• Announced achievement of primary endpoint in randomized, controlled pivotal study in pediatric ADHD in Q4 2017

• Announced achievement of primary endpoint in randomized, controlled study of AKL-T03 in major depressive disorder in December 2019

• Completed $68M financing round in Q2 2018• FDA filing for AKL-T01 in pediatric ADHD in Q2 2018• Announced partnership with Shionogi in March 2019

• EndeavorRx will be released as the centerpiece of the Endeavor Care Program, which includes the EndeavorRxtreatment and Akili CareTM

• The EndeavorRx treatment will be available with a prescription to families soon

AKL-T02 Pediatric autism (~1.5M)

AKL-T03 MDD (~17M), MS (~900K)

AKL-T04 MDD (~17M)

Product Candidate Details (3 of 3)

62

* PureTech is not responsible for development of all of these product candidates and FDA-cleared product. Our Non-Controlled Founded Entities and certain of our Controlled Founded Entities, Follica and Vedanta, have independent development teams and PureTech does not control the day-to-day development of their respective product candidates. However, with respect to these Controlled Founded Entities, we exert control through majority stock ownership, board representation, and voting decisions. ** As of 31 December 2019, Controlled Founded Entities include Alivio Therapeutics, Inc., Follica, Incorporated, Entrega, Inc., Vedanta Biosciences, Inc. and Sonde Health, Inc., and Non-Controlled Founded Entities include Akili Interactive Labs, Inc., Gelesis, Inc., Karuna Therapeutics, Inc., Vor Biopharma Inc. and, for all periods prior to December 18, 2019, resTORbio, Inc. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of December 31, 2019 (with the exception of Gelesis ownership which is as of April 1, 2020), including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Ownership of Vor (calculated as of June 30, 2020) and Sonde is based on the assumption that all future tranches of their most recent financing rounds are funded. Karuna ownership is calculated on an outstanding voting share basis as of May 26, 2020.; R PureTech Health has a right to royalty payments as a percentage of net sales.; †Products are investigational and have not been cleared by the FDA for use in the United States.; 1Following the completion of a successful End-of-Phase 2 meeting with the U.S. FDA, Karuna remains on track to initiate the Phase 3 program by the end of 2020.

Product Candidate*

PureTech Ownership**

Indication(US Patient Population)

Potential Key Differentiation Results & Milestones Expected milestones

Plenity®

(GS100)22.0%(Gelesis) R

Overweight and obesity (~150M) Only prescription weight management product to be FDA-cleared for use by overweight adults with a BMI as low as 25 kg/m2, with and without comorbidities such as hypertension, type 2 diabetes, or dyslipidemia

• Plenity® received FDA clearance as an aid for weight management in adults with a Body Mass Index (BMI) of 25-40 kg/m2, when used in conjunction with diet and exercise

• CE mark approval to market Plenity throughout the European Economic Area

• Announced partnership with Ro to support US commercialization of Plenity

• Announced partnership with China Medical System Holdings Ltd. for the commercialization of Plenity in China

• Presented data from first-in-human, randomized, double-blind, placebo-controlled study of Gelesis200 in Q2 2016

• Initiated proof-of-concept study of Gelesis200, optimized for patients with prediabetes and type 2 diabetes, in Q1 2017

• Initiated a Plenity early experience program in the United States in the second half of 2019

• Plans to bring Plenity to the US first, where it is now available to a limited extent while the company ramps up its commercial operations and inventory for a broad launch in 2021

• Expect to initiate a Phase 2 study for NASH/NAFLD in 2020

• Results are anticipated from the Gelesis200 LIGHT-UP study for weight loss and glycemic control in people with prediabetes or type 2 diabetes in 2021

• Plans to initiate a Phase 2 study of GS100 for weight management in adolescents with overweight and obesity in 2021

• Initiation of Phase 3 study of GS500 for chronic idiopathic constipation in 2020

GS100† Adolescent overweight and obesity Developing oral therapeutics based on a novel, superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal (GI) pathway

Gelesis200† Weight management in T2D (~80M) and prediabetes (~34M)

GS500† CIC (~35M)

GS300† NASH/NAFLD (80 – 100M)

GS400† IBD (~3M)

KarXT 18.1%(Karuna) R

Schizophrenia (~2.7M), Dementia related psychosis (~1.2M), pain

Designed to preferentially simulate M1/M4 muscarinic receptors in the brain without stimulating muscarinic receptors in peripheral tissues to significantly improve tolerability

• Announced its Phase 2 study of KarXT for schizophrenia met the primary endpoint with a statistically significant (P<0.0001) and clinically meaningful 11.6 point improvement on the PANSS total score from baseline vs. placebo in Q4 2019

• Completed $42M and $82M financings in Q3 2018 and H1 2019• IPO on Nasdaq in June 2019 (Nasdaq: KRTX), raising $103M• Completed a follow-on offering of 2,600,000 shares of common stock,

with gross proceeds of approximately $250M

• Phase 3 initiation by end of 20201

• Topline Phase 1b pain data in healthy volunteers mid-2020

• Topline Phase 1b data in healthy elderly volunteers by YE 2020

VOR33 11.8%(Vor)

AML (~60K) Novel approach for targeting cancer selectivity be addressing the detrimental effects of on-target toxicity to healthy tissue by developing engineered hematopoietic stem cells (eHSCs) for the treatment of hematological cancers

• In May 2019, preclinical research was published in the scientific journal Proceedings of the National Academy of Sciences supporting novel approach to treating cancer via eHSCs

• In January 2020, held a pre-IND meeting with the FDA• Obtained ex vivo proof-of-concept data for technology• Granted foundational intellectual property which covers therapeutic

approach

• Initiation of Phase 1 study in acute myeloid leukemia in 2021